Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis. J of Skin [Internet]. 2023 Nov. 13 [cited 2026 Apr. 19];7(6):s282. Available from: https://skin.dermsquared.com/skin/article/view/2390